MedTrace Logo

Treatment of GLP-1 for Diabetic Bariatric Patients

NCT04624672 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2023-11-14

Study results available
· View outcomes & findings →

Summary

This study is for patients that are diabetic, and require insulin for glycemic control, and going through the bariatric surgery process. This is a prospective study that is trying to determine if the introduction of a semaglutide increases the remission rates of diabetes post-operatively.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Semaglutide (1 Mg Dose)

Weekly injection of study drug for 4-6 months prior to Roux-en-Y gastric bypass surgery

DRUG

Placebo

Weekly injection of placebo for 4-6 months prior to Roux-en-Y gastric bypass surgery

Sponsors & Collaborators

Principal Investigators

  • Christopher Still, DO · Geisinger Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-25
Primary Completion
2022-07-18
Completion
2022-08-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04624672 on ClinicalTrials.gov